Salix Coronary Plaque vs IM007
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A is an AI-driven diagnostic tool focused on analyzing CCTA scans for coronary artery plaque and stenosis, aiding in the diagnosis of coronary artery disease. Tool B is an AI-powered remote monitoring platform that aggregates data from cardiac implantable electronic devices to streamline workflows and manage alerts for patients with various cardiac conditions. While both operate in cardiology with AI, their distinct data sources and primary functions make them suitable for different clinical needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Artrya Salix Coronary Plaque (Tool A) is designed for the rapid and accurate diagnosis of coronary artery disease (CAD) by assessing coronary artery plaque and stenosis from CCTA scans. Implicity IM007 (Tool B) aims to streamline remote cardiac monitoring workflows, reduce false alerts from cardiac implantable electronic devices (CIEDs), and improve patient outcomes in cardiology and heart failure management.
Tool A, Salix Coronary Plaque, analyzes CCTA (Coronary CT Angiography) scans to provide insights into coronary artery plaque and stenosis. Tool B, IM007, aggregates and analyzes data from various cardiac implantable electronic devices (CIEDs) from multiple manufacturers, including Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort.
Tool A provides near real-time, point-of-care assessment with integrated workflow management and automated, editable report generation. Tool B offers unified device data aggregation, smart workflow automation for billing, reporting, and scheduling, and features bidirectional API and integration framework for EHR integration.
Tool A utilizes AI for the detection and quantification of coronary plaque, identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), stenosis assessment, and calcium scoring. Tool B features AI-driven alert management to reduce false positives (e.g., 79% for ILR ECG Analyzer, 85% for AF alerts), an FDA-cleared AI for ICM ECG data analysis (ILR ECG Analyzer), and a predictive AI for heart failure hospitalization risk (SignalHF).
Tool A, Salix Coronary Plaque, qualifies for a US CPT reimbursement rate of US$950 per assessment as of January 1, 2026. HIPAA compliance and a Business Associate Agreement (BAA) are not explicitly stated for the product. Tool B, IM007, explicitly states it is HIPAA compliant and has a BAA available, and its platform includes automated billing and compliance features to maximize reimbursement for remote monitoring services.
Tool A, Salix Coronary Plaque, is designed for use by specialists in Cardiology and Radiology. Tool B, IM007, is primarily intended for Cardiology and Hospital Medicine, focusing on remote monitoring and heart failure management.